Equillium (EQ) to Release Quarterly Earnings on Monday

Equillium (NASDAQ:EQ) is anticipated to announce its earnings results before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Equillium Stock Performance

NASDAQ:EQ opened at $0.75 on Monday. The firm’s fifty day moving average is $0.76 and its 200-day moving average is $0.81. Equillium has a 52 week low of $0.49 and a 52 week high of $2.99. The firm has a market cap of $26.75 million, a P/E ratio of -5.39 and a beta of 1.87.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.